The effects of bufadienolides on HER2 overexpressing breast cancer cells

[1]  N. Nass,et al.  Tamoxifen resistance: from cell culture experiments towards novel biomarkers. , 2015, Pathology, research and practice.

[2]  MD Justine MacNeil.  Plos One , 2015 .

[3]  X. Bian,et al.  Disruption of the ER-α36-EGFR/HER2 Positive Regulatory Loops Restores Tamoxifen Sensitivity in Tamoxifen Resistance Breast Cancer Cells , 2014, PloS one.

[4]  L. Liao,et al.  NCOA1 Directly Targets M-CSF1 Expression to Promote Breast Cancer Metastasis. , 2014, Cancer research.

[5]  A. Hill,et al.  Global gene repression by the steroid receptor coactivator SRC-1 promotes oncogenesis. , 2014, Cancer research.

[6]  P. Griffin,et al.  Bufalin is a potent small-molecule inhibitor of the steroid receptor coactivators SRC-3 and SRC-1. , 2014, Cancer research.

[7]  E. Andrechek.  HER2/Neu tumorigenesis and metastasis is regulated by E2F activator transcription factors , 2013, Oncogene.

[8]  K. Fung,et al.  Arenobufagin, a natural bufadienolide from toad venom, induces apoptosis and autophagy in human hepatocellular carcinoma cells through inhibition of PI3K/Akt/mTOR pathway. , 2013, Carcinogenesis.

[9]  F. Jänicke,et al.  Prognostic relevance of AIB1 (NCoA3) amplification and overexpression in breast cancer , 2013, Breast Cancer Research and Treatment.

[10]  J. Xu,et al.  Arenobufagin, a bufadienolide compound from toad venom, inhibits VEGF-mediated angiogenesis through suppression of VEGFR-2 signaling pathway. , 2012, Biochemical pharmacology.

[11]  H. Park,et al.  Clinical significance of progesterone receptor and HER2 status in estrogen receptor-positive, operable breast cancer with adjuvant tamoxifen , 2011, Journal of Cancer Research and Clinical Oncology.

[12]  C. Marth,et al.  Resistance to HER2-targeted therapy: mechanisms of trastuzumab resistance and possible strategies to overcome unresponsiveness to treatment , 2010, Wiener Medizinische Wochenschrift.

[13]  Changkai Sun,et al.  Preparative separation and purification of bufadienolides from Chinese traditional medicine of ChanSu using high-speed counter-current chromatography. , 2010, Journal of separation science.

[14]  C. Parise,et al.  Breast Cancer Subtypes as Defined by the Estrogen Receptor (ER), Progesterone Receptor (PR), and the Human Epidermal Growth Factor Receptor 2 (HER2) among Women with Invasive Breast Cancer in California, 1999–2004 , 2009, The breast journal.

[15]  Jeffrey S Ross,et al.  Breast cancer biomarkers and HER2 testing after 10 years of anti-HER2 therapy. , 2009, Drug news & perspectives.

[16]  D. Guo,et al.  Simultaneous determination and pharmacokinetics of five bufadienolides in rat plasma after oral administration of Chansu extract by SPE-HPLC method. , 2008, Journal of pharmaceutical and biomedical analysis.

[17]  Jianming Xu,et al.  Genetic screening reveals an essential role of p27kip1 in restriction of breast cancer progression. , 2007, Cancer research.

[18]  A. Wellstein,et al.  Epidermal growth factor receptor tyrosine phosphorylation and signaling controlled by a nuclear receptor coactivator, amplified in breast cancer 1. , 2007, Cancer research.

[19]  John M.S. Bartlett,et al.  Amplified in Breast Cancer 1 in Human Epidermal Growth Factor Receptor–Positive Tumors of Tamoxifen-Treated Breast Cancer Patients , 2007, Clinical Cancer Research.

[20]  H. Saavedra,et al.  Control of the p53-p21CIP1 Axis by E2f1, E2f2, and E2f3 Is Essential for G1/S Progression and Cellular Transformation* , 2006, Journal of Biological Chemistry.

[21]  M. Ittmann,et al.  Steroid receptor coactivator-3 and activator protein-1 coordinately regulate the transcription of components of the insulin-like growth factor/AKT signaling pathway. , 2006, Cancer research.

[22]  David G Johnson,et al.  Distinct and Overlapping Roles for E2F Family Members in Transcription, Proliferation and Apoptosis. , 2006, Current molecular medicine.

[23]  L. Cantley,et al.  Ras, PI(3)K and mTOR signalling controls tumour cell growth , 2006, Nature.

[24]  N. Normanno,et al.  Epidermal growth factor receptor (EGFR) signaling in cancer. , 2006, Gene.

[25]  T. Chou,et al.  Mutation in the Tyrosine Kinase Domain of Epidermal Growth Factor Receptor Is a Predictive and Prognostic Factor for Gefitinib Treatment in Patients with Non–Small Cell Lung Cancer , 2005, Clinical Cancer Research.

[26]  K. Helin,et al.  E2F target genes: unraveling the biology. , 2004, Trends in biochemical sciences.

[27]  R. Schiff,et al.  Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. , 2004, Journal of the National Cancer Institute.

[28]  M. Louie,et al.  ACTR/AIB1 Functions as an E2F1 Coactivator To Promote Breast Cancer Cell Proliferation and Antiestrogen Resistance , 2004, Molecular and Cellular Biology.

[29]  A. Citri,et al.  The deaf and the dumb: the biology of ErbB-2 and ErbB-3. , 2003, Experimental cell research.

[30]  S. Hilsenbeck,et al.  Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. , 2003, Journal of the National Cancer Institute.

[31]  Hyun-soo Cho,et al.  Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab , 2003, Nature.

[32]  E. Levin,et al.  Proximal Events in Signaling by Plasma Membrane Estrogen Receptors* , 2003, The Journal of Biological Chemistry.

[33]  J. Qin,et al.  Regulation of SRC-3 (pCIP/ACTR/AIB-1/RAC-3/TRAM-1) Coactivator Activity by IκB Kinase , 2002, Molecular and Cellular Biology.

[34]  J. Nevins,et al.  The Rb/E2F pathway and cancer. , 2001, Human molecular genetics.

[35]  M. Southey,et al.  Overexpression of the steroid receptor coactivator AIB1 in breast cancer correlates with the absence of estrogen and progesterone receptors and positivity for p53 and HER2/neu. , 2001, Cancer research.

[36]  O. Hermanson,et al.  Regulation of somatic growth by the p160 coactivator p/CIP. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[37]  J. Font de Mora,et al.  AIB1 Is a Conduit for Kinase-Mediated Growth Factor Signaling to the Estrogen Receptor , 2000, Molecular and Cellular Biology.

[38]  C. Deng,et al.  The steroid receptor coactivator SRC-3 (p/CIP/RAC3/AIB1/ACTR/TRAM-1) is required for normal growth, puberty, female reproductive function, and mammary gland development. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[39]  C. Glass,et al.  The coregulator exchange in transcriptional functions of nuclear receptors. , 2000, Genes & development.

[40]  N. Koibuchi,et al.  TRAM-1, A Novel 160-kDa Thyroid Hormone Receptor Activator Molecule, Exhibits Distinct Properties from Steroid Receptor Coactivator-1* , 1997, The Journal of Biological Chemistry.

[41]  P. Meltzer,et al.  AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. , 1997, Science.

[42]  Y. Yarden,et al.  A single autophosphorylation site confers oncogenicity to the Neu/ErbB‐2 receptor and enables coupling to the MAP kinase pathway. , 1994, The EMBO journal.

[43]  W. Gullick,et al.  Identification of c‐erbB‐3 binding sites for phosphatidylinositol 3′‐kinase and SHC using an EGF receptor/c‐erbB‐3 chimera. , 1994, The EMBO journal.

[44]  H. Matsuda,et al.  Depressive effects of arenobufagin on the delayed rectifier K+ current of guinea-pig cardiac myocytes. , 1994, European journal of pharmacology.

[45]  H. Matsuda,et al.  Arenobufagin, a compound in toad venom, blocks Na(+)-K+ pump current in cardiac myocytes. , 1993, European journal of pharmacology.

[46]  C. Osborne,et al.  Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu , 1992, Breast Cancer Research and Treatment.

[47]  J. Cairns,et al.  Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer. , 1992, British Journal of Cancer.

[48]  W Godolphin,et al.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.

[49]  A. Jemal,et al.  Cancer statistics, 2014 , 2014, CA: a cancer journal for clinicians.

[50]  Jianfeng Cai,et al.  Anti-tumor activity and apoptosis-regulation mechanisms of bufalin in various cancers: new hope for cancer patients. , 2012, Asian Pacific journal of cancer prevention : APJCP.

[51]  J. Qin,et al.  Regulation of SRC-3 (pCIP/ACTR/AIB-1/RAC-3/TRAM-1) Coactivator activity by I kappa B kinase. , 2002, Molecular and cellular biology.

[52]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.